Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrystal Amber Regulatory News (CRS)

Share Price Information for Crystal Amber (CRS)

Share Price is delayed by 15 minutes
Get Live Data
100.00    -1.00 (-0.99%)
Bid:
98.00
Ask:
102.00
Spread: 4.00 (4.082%)
Market Cap: £59.53m
CRS Live PriceLast checked at - London Stock Exchange

Intraday Crystal Amber Share Chart

Update on shareholder returns

30 Sep 2022 07:01

RNS Number : 2567B
Crystal Amber Fund Limited
30 September 2022
 

30 September 2022

CRYSTAL AMBER FUND LIMITED

("Crystal Amber Fund" or the "Fund")

 

Update on shareholder returns

 

Net asset performance has remained positive: over the last three months, net asset value per share has risen by 3.4 per cent and over the last year by 4.7 per cent. Over the same periods, the UK mid cap index has fallen by 27.1 per cent and by 42.5 per cent.

To date in 2022, the Fund has returned 20p a share in dividends to shareholders (representing a gross return of GBP16.7 million),

The Fund expects to provide an update shortly on additional shareholder returns based on the Investment Manager's and the Board's assessment of the status and timing of anticipated corporate transactions.

The Fund notes that Hurricane Energy plc ("Hurricane") has reported that at 31 July 2022, it held net cash of $89 million. At current exchange rates, this is equivalent to £82 million. Crystal Amber holds 28.9 per cent of Hurricane's issued share capital.

 

 

For further enquiries please contact:

 

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com

 

Allenby Capital Limited - Nominated Adviser

David Worlidge/Freddie Wooding

Tel: 020 3328 5656

 

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

 

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDMZGZLGLFGZZZ
Date   Source Headline
16th Aug 20249:45 amRNSDirector/PDMR Shareholding
16th Aug 20249:43 amRNSTransaction in Own Shares and Total Voting Rights
15th Aug 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
14th Aug 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
12th Aug 20247:00 amRNSExtension to Share Buyback Programme
31st Jul 20245:00 pmRNSTotal Voting Rights
31st Jul 202411:50 amRNSInvestee company update: Morphic Medical Inc.
31st Jul 202411:07 amRNSMonthly Net Asset Value
26th Jul 20244:06 pmRNSTransaction in Own Shares and Total Voting Rights
23rd Jul 20246:04 pmRNSTransaction in Own Shares and Total Voting Rights
3rd Jul 20245:42 pmRNSTransaction in Own Shares and Total Voting Rights
28th Jun 20245:15 pmRNSTotal Voting Rights
21st Jun 20245:00 pmRNSTransaction in Own Shares and Total Voting Rights
19th Jun 202410:07 amRNSMonthly Net Asset Value
18th Jun 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
7th Jun 20244:49 pmRNSTransaction in Own Shares and Total Voting Rights
6th Jun 20245:15 pmRNSTransaction in Own Shares and Total Voting Rights
5th Jun 20245:43 pmRNSTransaction in Own Shares and Total Voting Rights
4th Jun 202412:11 pmRNSHolding(s) in Company
4th Jun 202412:11 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNSMorphic Medical – FDA approval of study amendments
3rd Jun 20245:33 pmRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20247:00 amRNSTotal Voting Rights
31st May 20245:39 pmRNSTransaction in Own Shares
31st May 20247:00 amRNSTransaction in Own Shares
23rd May 20241:21 pmRNSMonthly Net Asset Value
23rd May 20247:00 amRNSExtension to Share Buyback Programme
22nd May 20247:00 amRNSTransaction in Own Shares
17th May 20245:49 pmRNSTransaction in Own Shares
3rd May 20246:22 pmRNSHolding(s) in Company
2nd May 202412:37 pmRNSHolding(s) in Company
1st May 20245:22 pmRNSTransaction in Own Shares
30th Apr 20245:37 pmRNSTotal Voting Rights
29th Apr 20243:26 pmRNSHolding(s) in Company
26th Apr 20245:27 pmRNSTransaction in Own Shares
25th Apr 20247:00 amRNSHolding(s) in Company
24th Apr 20244:00 pmRNSMonthly Net Asset Value
24th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20246:22 pmRNSTransaction in Own Shares
10th Apr 20249:34 amRNSTransaction in Own Shares
3rd Apr 20244:44 pmRNSMonthly Net Asset Value
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:30 pmRNSExtension to Share Buyback Programme
28th Mar 20246:01 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSHalf-year Report
27th Mar 20246:27 pmRNSTransaction in Own Shares
22nd Mar 20245:09 pmRNSTransaction in Own Shares
18th Mar 20245:29 pmRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20245:30 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.